VANDA PHARMACEUTICALS INC. (VNDA) Current Ratio
- Current ratio · latest quarter: Value 1.61×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.61× | Current assets / current liabilities. $264.48M ÷ $164.03M ≈ 1.61× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 264.48M USD | Assets, Current |
| Current obligations | 164.03M USD | Liabilities, Current |
| Cash and equivalents | 55.88M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 59.69M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 1.68M USD | Inventory, Net |
| Payables | (m) | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $264.48M | $164.03M | $55.88M | (m) | $59.69M | $1.68M | (m) | (m) | 1.61× |
| 2026-03-31 | $293.17M | $135.58M | $54.03M | (m) | $56.88M | $1.70M | (m) | (m) | 2.16× |
| 2025-12-31 | $347.26M | $145.16M | $84.85M | (m) | $54.58M | $1.85M | (m) | (m) | 2.39× |
| 2025-09-30 | $367.50M | $117.87M | $70.02M | (m) | $50.54M | $2.04M | (m) | (m) | 3.12× |
| 2025-06-30 | $394.92M | $121.49M | $80.98M | (m) | $44.99M | $2.17M | (m) | (m) | 3.25× |
| 2025-03-31 | $407.91M | $103.92M | $111.80M | (m) | $44.60M | $1.92M | (m) | (m) | 3.93× |
| 2024-12-31 | $438.89M | $99.98M | $102.32M | (m) | $47.10M | $1.73M | (m) | (m) | 4.39× |
| 2024-09-30 | $432.39M | $89.09M | $100.50M | (m) | $42.75M | $1.61M | (m) | (m) | 4.85× |
| 2024-06-30 | $439.18M | $93.79M | $102.95M | (m) | $41.86M | $1.47M | (m) | (m) | 4.68× |
| 2024-03-31 | $439.43M | $93.34M | $125.16M | (m) | $36.71M | $1.50M | (m) | (m) | 4.71× |
| 2023-12-31 | $432.95M | $87.70M | $135.82M | (m) | $34.16M | $1.36M | (m) | (m) | 4.94× |
| 2023-09-30 | $536.57M | $84.84M | $183.19M | (m) | $29.27M | $1.01M | (m) | (m) | 6.32× |
| 2023-06-30 | $533.50M | $87.40M | $150.03M | (m) | $33.62M | $1.08M | (m) | (m) | 6.10× |
| 2023-03-31 | $533.71M | $93.79M | $354.17M | (m) | $24.51M | $1.10M | (m) | (m) | 5.69× |
| 2022-12-31 | $519.29M | $91.44M | $135.03M | (m) | $33.51M | $1.19M | (m) | (m) | 5.68× |
| 2022-09-30 | $507.11M | $92.62M | $49.40M | (m) | $29.35M | $1.59M | (m) | (m) | 5.47× |
| 2022-06-30 | $496.89M | $88.40M | $58.23M | $382.63M | $28.80M | $1.50M | (m) | (m) | 5.62× |
| 2022-03-31 | $492.27M | $90.74M | $66.93M | $368.25M | $30.50M | $1.29M | (m) | (m) | 5.42× |
| 2021-12-31 | $478.30M | $74.42M | $52.07M | (m) | $32.47M | $1.02M | (m) | (m) | 6.43× |
| 2021-09-30 | $461.81M | $72.00M | $50.52M | $355.45M | $41.50M | $902.00K | (m) | (m) | 6.41× |
| 2021-06-30 | $446.65M | $71.99M | $57.24M | $339.25M | $37.09M | $1.05M | (m) | (m) | 6.20× |
| 2021-03-31 | $421.22M | $61.78M | $72.13M | $306.03M | $31.47M | $1.36M | (m) | (m) | 6.82× |
| 2020-12-31 | $409.14M | $65.94M | $61.03M | $306.71M | $30.04M | $1.28M | (m) | (m) | 6.21× |
| 2020-09-30 | $389.53M | $61.36M | $56.97M | $291.57M | $28.03M | $1.32M | (m) | (m) | 6.35× |
| 2020-06-30 | $380.86M | $61.59M | $95.31M | $244.54M | $24.59M | $1.38M | (m) | (m) | 6.18× |
| 2020-03-31 | $360.75M | $59.22M | $64.95M | $247.38M | $29.27M | $1.32M | (m) | (m) | 6.09× |
| 2019-12-31 | $354.14M | $59.51M | $45.07M | $267.06M | $26.37M | $1.14M | (m) | (m) | 5.95× |
| 2019-09-30 | $280.01M | $60.00M | $39.21M | $198.58M | $26.82M | $1.02M | (m) | (m) | 4.67× |
| 2019-06-30 | $315.80M | $62.58M | $46.54M | $233.62M | $23.89M | $1.06M | (m) | (m) | 5.05× |
| 2019-03-31 | $306.50M | $59.27M | $34.38M | $233.46M | $26.35M | $1.11M | (m) | (m) | 5.17× |
| 2018-12-31 | $299.13M | $53.02M | $61.01M | $196.35M | $28.78M | $994.00K | (m) | (m) | 5.64× |
| 2018-09-30 | $278.81M | $46.24M | $60.78M | $179.80M | $25.26M | $887.00K | (m) | (m) | 6.03× |
| 2018-06-30 | $269.10M | $46.88M | $60.89M | $170.32M | $24.86M | $1.19M | (m) | (m) | 5.74× |
| 2018-03-31 | $282.44M | $71.95M | $155.29M | $93.54M | $23.31M | $1.01M | (m) | (m) | 3.93× |
| 2017-12-31 | $169.86M | $70.36M | $33.63M | $109.79M | $17.60M | $840.00K | (m) | (m) | 2.41× |
| 2017-09-30 | $169.72M | $71.54M | $22.59M | $117.30M | $18.18M | $921.00K | (m) | (m) | 2.37× |
| 2017-06-30 | $174.61M | $75.44M | $14.23M | $122.89M | $21.02M | $742.00K | (m) | (m) | 2.31× |
| 2017-03-31 | $168.56M | $72.97M | $20.11M | $117.64M | $17.75M | $816.00K | (m) | (m) | 2.31× |
| 2016-12-31 | $174.18M | $50.32M | $40.43M | $100.91M | $20.27M | $779.00K | (m) | (m) | 3.46× |
| 2016-09-30 | $170.41M | $50.68M | $32.77M | $109.81M | $15.93M | $865.00K | (m) | (m) | 3.36× |
| 2016-06-30 | $160.38M | $51.76M | $23.19M | $112.80M | $14.03M | $927.00K | (m) | (m) | 3.10× |
| 2016-03-31 | $162.45M | $55.04M | $38.74M | $99.59M | $16.68M | $938.00K | (m) | (m) | 2.95× |
| 2015-12-31 | $166.55M | $51.32M | $50.84M | $92.34M | $16.33M | $1.29M | (m) | (m) | 3.25× |
| 2015-09-30 | $173.88M | $45.89M | $46.79M | $97.53M | $15.79M | $3.80M | (m) | (m) | 3.79× |
| 2015-06-30 | $174.37M | $45.19M | $48.34M | $98.30M | $15.82M | $4.96M | $1.63M | (m) | 3.86× |
| 2015-03-31 | $162.17M | $31.79M | $32.81M | $101.52M | $20.12M | $5.21M | $1.49M | (m) | 5.10× |
| 2014-12-31 | $141.73M | $7.79M | $60.90M | $68.92M | $3.65M | $5.17M | (m) | (m) | 18.20× |
| 2014-09-30 | $64.84M | $38.84M | $15.31M | $40.78M | $3.70M | $1.27M | $547.00K | (m) | 1.67× |
| 2014-06-30 | $71.22M | $38.29M | $16.99M | $46.59M | $2.38M | $1.09M | $248.00K | (m) | 1.86× |
| 2014-03-31 | $105.52M | $45.40M | $43.26M | $57.14M | $1.69M | $192.00K | $953.00K | (m) | 2.32× |
| 2013-12-31 | $135.61M | $32.85M | $64.76M | $65.59M | $2.03M | (m) | $661.00K | (m) | 4.13× |
| 2013-09-30 | $147.07M | $31.91M | $142.17M | (m) | $1.96M | (m) | $369.00K | (m) | 4.61× |
| 2013-06-30 | $108.36M | $31.93M | $103.63M | (m) | $1.64M | $28.00K | $1.17M | (m) | 3.39× |
| 2013-03-31 | $116.11M | $31.97M | $109.93M | $1.00M | $1.46M | $21.00K | $1.11M | (m) | 3.63× |
| 2012-12-31 | $125.97M | $32.26M | $88.77M | $31.63M | $1.17M | (m) | $287.00K | (m) | 3.90× |
| 2012-09-30 | $139.85M | $34.63M | $104.52M | $29.89M | $1.53M | $161.00K | $1.09M | (m) | 4.04× |
| 2012-06-30 | $149.99M | $34.39M | $94.39M | $50.31M | $1.70M | $165.00K | $1.69M | (m) | 4.36× |
| 2012-03-31 | $161.35M | $32.66M | $108.09M | $49.16M | $1.53M | (m) | $780.00K | (m) | 4.94× |
| 2011-12-31 | $153.50M | $31.62M | $87.92M | $60.96M | $1.62M | (m) | $996.00K | (m) | 4.85× |
| 2011-09-30 | $164.72M | $33.64M | $60.33M | $101.12M | $1.22M | (m) | $1.33M | (m) | 4.90× |
| 2011-06-30 | $191.53M | $32.86M | $50.39M | $138.01M | $752.00K | (m) | $1.34M | (m) | 5.83× |
| 2010-12-31 | $200.57M | $31.03M | $42.56M | $155.48M | $511.00K | (m) | $648.00K | (m) | 6.46× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |